• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

Unmet Medical Need Analysis in sickle cell disease: Approval of OXBRYTA (voxelotor)

On Nov 25, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

Unmet Medical Need ParametersUnmet Medical Need in sickle cell disease after SIKLOSUnmet Medical Need in sickle cell disease after OXBRYTA
Treatment Adequacy Current treatment increases hemoglobin F levels in red blood cells (RBCs), decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium.New treatment increases the affinity of Hb for oxygen, inhibition of HbS polymerization, inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.
Disease Severity• Vaso-occlusive crisis and chronic pain are associated with considerable economic loss and disability
• Approved in pediatric patients, 2 years of age and older
• Vaso-occlusive crisis and chronic pain are associated with considerable economic loss and disability
• Approved in adults and pediatric patients 12 years of age and older.
Concerns of Payers & Providers• Hemoglobin F percentage change
• Vasoocclusive episodes frequency
• Acute chest syndrome frequency
• Hospitalization rate related to SCD
• Blood transfusion need
• Hemoglobin F percentage change
Net Unmet Medical Need Score2.46/52.50/5
Low to moderate unmet medical needLow to moderate unmet medical need

OXBRYTA has disease modifying effect, increases the affinity of Hb for oxygen, inhibition of HbS polymerization, inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.

To get detailed analysis of unmet medical need and to understand our approach which we are using for unmet medical analysis of any disease please contact at [email protected]

We help researchers in unmet medical need analysis of diseases which helps them in disease prioritization for any new drug/device/target/MOA development. We do unmet medical need analysis of any disease based on various parameters which is not limited to treatment adequacy, patient perspective, payer & providers perspective.

Leave a Reply

Your email address will not be published.

Contact
+91 9643310025, 9643312749
© 2019 Pharmintel